Compound class:
Antibody
Comment: COVA322 is a bispecific TNF/IL-17A inhibitor that was designed by Covagen for the treatment of inflammatory diseases including psoriasis, psoriatic arthritis, and rheumatoid arthritis [2]. Structurally COVA322 is a fusion protein containing an antibody that binds to TNF (in this case the light chain of adalimumab) and a Fyn SH3-derived protein (Fynomer) that binds to IL-17A [1]. The fusion protein was produced in transiently transfected Chinese hamster ovary (CHO) cells. COVA322 was able to simultaneously bind TNF and IL-17A.
Clinical development of COVA322 was discontinued due to an unacceptable safety profile that was detected in Phase 1 trial. |
Immunopharmacology Comments |
COVA322 was advanced to Phase 1 clinical evaluation in patients with stable chronic moderate-to-severe plaque psoriasis. Unfortunately the study (NCT02243787) was terminated when it became evident that COVA322's safety profile was unacceptable. |
Immunopharmacology Disease | |||
Disease | X-Refs | Comment | References |
Psoriasis |
Disease Ontology:
DOID:8893 |
Failed Phase 1 clinical lead for plaque psoriasis. Concerns about COVA322's safety profile led to development being discontinued. |